Drug firm Alkem Laboratories Ltd. on Tuesday said it has entered an asset purchase agreement with AbbVie Inc., U.S, for the acquisition of certain assets related to the active pharmaceutical ingredient, Dronabinol, for over $10 million (approximately Rs 71 crore).
The assets related to Dronabinol include domain names and trademarks pertaining to 'Marinol', New Drug Application registration with U.S. Food and Drug Administration for Marinol, logos, patents designs, know-how, technical and manufacturing instructions, inventory, manufacturing equipment, and such items, Alkem Laboratories said in a filing to BSE.
The cost of acquisition is cash consideration of $10 million-plus suitable working capital adjustments on closing, it added. The objects of the acquisition are, "The company shall own the NDA and associated assets and will use these to commercially exploit both branded and generic sales in the U.S.," Alkem Laboratories said.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
